文献速递泌尿生殖与妇科肿瘤放疗

全国多中心回顾性研究:高剂量率近距离放疗作为前列腺癌单一疗法

Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-12-18

日本5家机构1995至2013年回顾性分析524例低、中、高危前列腺癌患者,接受高剂量率近距离放疗(HDR-BT)单一治疗,中位随访5.9年。全组5年生化无病生存率92%、总生存率97%、病因特异性生存率99%、无转移生存率94%;低/中/高危5年生化无病生存率分别为95%/94%/89%。结论认为HDR-BT单一疗法对各级风险前列腺癌安全有效。

要点

  • 全组5年生化无病生存率92%,总生存率97%,病因特异性生存率99%。
  • 低/中/高危5年生化无病生存率分别为95%/94%/89%。
  • 5年晚期2-3级泌尿生殖毒性累积发生率19%,3级仅1%。

核心结论

  • HDR-BT单一疗法对低、中、高危前列腺癌患者安全有效。

研究设计与样本

  • 日本5家机构1995至2013年 nationwide、多中心、回顾性研究,共524例前列腺癌患者接受HDR-BT单一治疗。
  • 风险分组:低危73例(14%)、中危207例(40%)、高危244例(47%)。
  • 剂量分割包括27 Gy/2次(69例,13%)、45.5 Gy/7次(168例,32%)、49 Gy/7次(149例,28%)、54 Gy/9次(130例,25%)及其他(8例,2%)。
  • 156例(30%)未接受雄激素剥夺治疗(ADT),202例(39%)ADT<1年,112例(21%)1-3年,54例(10%)>3年。
  • 中位随访5.9年(范围0.4-18.1年),存活患者最少随访2年。

主要发现

  • 全组5年生化无病生存率92%、总生存率97%、病因特异性生存率99%、无转移生存率94%。
  • 低/中/高危患者5年生化无病生存率分别为95%/94%/89%。
  • 低/中/高危患者5年总生存率分别为98%/98%/94%。
  • 低/中/高危患者5年病因特异性生存率分别为98%/100%/98%。
  • 低/中/高危患者5年无转移生存率分别为98%/95%/90%。

关键数值与推荐

  • 5年晚期2-3级泌尿生殖毒性累积发生率为19%,3级为1%。
  • 5年晚期2-3级胃肠道毒性累积发生率为3%,3级为0%(0.2%)。
  • 未检测到4级或5级泌尿生殖或胃肠道毒性。

临床怎么用

  • 对于低、中、高危前列腺癌患者,HDR-BT单一疗法可作为安全有效的治疗选择。
  • 需关注晚期泌尿生殖毒性,5年2-3级累积发生率19%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present, analyze, and discuss results of a nationwide, multicenter, retrospective study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate-, and high-risk prostate cancer. METHODS AND MATERIALS: From 1995 through 2013, 524 patients, 73 (14%) with low-risk, 207 (40%) with intermediate-risk, and 244 (47%) with high-risk prostate cancer, were treated with HDR-BT as monotherapy at 5 institutions in Japan. Dose fractionations were 27 Gy/2 fractions for 69 patients (13%), 45.5 Gy/7 fractions for 168 (32%), 49 Gy/7 fractions for 149 (28%), 54 Gy/9 fractions for 130 (25%), and others for 8 (2%). Of these patients, 156 (30%) did not receive androgen deprivation therapy, and 202 patients (39%) did receive androgen deprivation therapy <1 year, 112 (21%) for 1-3 years, and 54 (10%) for >3 years. Median follow-up time was 5.9 years (range, 0.4-18.1 years), with a minimum of 2 years for surviving patients. RESULTS: After 5 years, respective actuarial rates of no biochemical evidence of disease, overall survival, cause-specific survival, and metastasis-free survival for all patients were 92%, 97%, 99%, and 94%. For low/intermediate/high-risk patients, the 5-year no biochemical evidence of disease rates were 95%/94%/89%, the 5-year overall survival rates were 98%/98%/94%, the 5-year cause-specific survival rates were 98%/100%/98%, and the 5-year metastasis-free survival rates were 98%/95%/90%, respectively. The cumulative incidence of late grade 2 to 3 genitourinary toxicity at 5 years was 19%, and that of late grade 3 was 1%. The corresponding incidences of gastrointestinal toxicity were 3% and 0% (0.2%). No grade 4 or 5 of either type of toxicity was detected. CONCLUSIONS: The findings of this nationwide, multicenter, retrospective study demonstrate that HDR-BT as monotherapy was safe and effective for all patients with low-, intermediate-, and high-risk prostate cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yoshioka Y, Kotsuma T, Komiya A, et al. Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28333018. doi:10.1016/j.ijrobp.2016.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。